SuperGen, Inc. To Present At RedChip Small-Cap Investor Conference
DUBLIN, Calif., April 21 /PRNewswire-FirstCall/ -- SuperGen, Inc. today announced that Edward L. Jacobs, Chief Operating Officer, is scheduled to present at the RedChip Small-Cap Investor Conference, being held at the Hard Rock Hotel in Hollywood, Florida on Friday, April 28, 2006 at 1:45 PM ET. Mr. Jacobs will provide a brief corporate overview and discuss the Company's recent progress.
About SuperGen
Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the, discovery, acquisition, rapid development and commercialization of therapies for solid tumors, hematological malignancies and blood disorders. SuperGen's portfolio includes Orathecin(TM) (rubitecan) capsules, an investigational drug intended for the treatment of pancreatic cancer, Nipent(R) (pentostatin for injection), Mitomycin, and Surface Safe(R) cleaner. In addition, a number of aurora-A tyrosine kinase inhibitors and DNA methyltransferase preclinical products are under development. For more information about SuperGen, please visit http://www.supergen.com.
Contacts: SuperGen Timothy L. Enns S.V.P., Corporate Communications& Business Development Tel: (925) 560-0100 x111 E-mail: tenns@supergen.com Noonan Russo Sharon Weinstein Director of Investor Relations Tel: (212) 845-4271 E-mail: sharon.weinstein@eurorscg.com
SuperGen, Inc.CONTACT: Timothy L. Enns, S.V.P., Corporate, Communications & BusinessDevelopment of SuperGen, +1-925-560-0100 x111, tenns@supergen.com; orSharon Weinstein, Director of Investor Relations of Noonan Russo,+1-212-845-4271, sharon.weinstein@eurorscg.com
Web site: http://www.supergen.com/